Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Baron Health Care Fund Neal Kaufman | “Teva Pharmaceutical Industries Limited ($TEVA) is an international pharmaceutical firm undergoing a strategic turnaround from a low-margin generic drug producer into an innovative biopharmaceutical specialist, accounting for 5.1% of the fund's assets. The manager expresses a bullish posture, emphasizing that the market has yet to fully appreciate the high-margin revenue contribution coming from its proprietary branded drug portfolio. The mechanics of the thesis rest on gross margin expansion and operating leverage derived from higher-margin patented drugs, notably Austedo, Ajovy, and Uzedy. This core proprietary basket surged 43% year-over-year to exceed $1 billion in quarterly revenue, driving a raised full-year target of $3.7 billion. As high-value branded sales increase as a percentage of total revenues, Teva's return on invested capital improves while generating robust free cash flow to accelerate corporate balance sheet deleveraging. Near-term catalysts include the transition from American Depositary Shares to a direct NYSE listing to expand institutional ownership and lower financing costs, alongside clinical advancements such as TEV '408 for celiac disease and regulatory reviews for pediatric Tourette syndrome. Crucial risks to track include potential litigation exposures, execution missteps in novel drug commercialization, and generic price deflation in legacy product lines.” | BULL | Q3 2026 Oct 14, 2026 | View Pitch |
Baron Health Care Fund Neal Kaufman | “Teva Pharmaceutical Industries Limited has historically been known for its large generics business but is increasingly focused on growing its innovative pharmaceutical business, which now represents roughly half of the company's profits. Austedo continues to see strong adoption in a significantly underpenetrated and underdiagnosed tardive dyskinesia market, Ajovy has gained share in chronic migraine, and Uzedy has launched successfully in schizophrenia. In addition, Teva is preparing to launch a long-acting formulation of olanzapine in the schizophrenia market. We are also encouraged by Teva's internally developed duvakitug, now partnered with Sanofi, which has the potential to become a pipeline-in-a-product across multiple autoimmune conditions. Shares rose during the quarter as the outcome of Medicare drug price negotiations for Austedo proved more favorable than investors had feared. BSD Analysis: Teva is the definition of a fallen giant that refuses to die. Years of debt, litigation, and generic price collapse crushed the equity — and deservedly so. What's changed is brutal cost discipline and a renewed focus on cash flow over growth illusions. Generics remain ugly, but stability matters more than heroics. Specialty drugs like Austedo provide a real, higher-quality earnings stream. Legal overhangs are shrinking, freeing up capital and attention. This is not a comeback growth story. It's a survival-and-repair story with leverage to normalization. If execution holds, the upside is asymmetric from depressed expectations.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
The Sound Shore Fund Harry Burn, III; John P. DeGulis; T. Gibbs Kane, Jr. | “As always, when there is a macro-led market drop, as we saw in March/April, we often take advantage of price dislocation and add to positions where we have the highest conviction. For example, drug manufacturer Teva Pharmaceutical was a name we added to as the company continues to execute on its plan to accelerate growth, primarily through the success of its pipeline. BSD Analysis: Teva is a deep-value, high-stakes generic drug turnaround play whose stock is poised for a massive re-rating following the successful deleveraging of its balance sheet. The core thesis is driven by the successful resolution of massive U.S. litigation (opioids and price-fixing) and a disciplined focus on paying down its historic $34 billion debt load. The company's moat is its global dominance in generic pharmaceuticals and its specialty pipeline, including the migraine drug Ajovy. The stock is a high-conviction bet on the new management's ability to convert its clean balance sheet and market leadership into sustained Free Cash Flow and eventual dividend restoration.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.